芳香化酶抑制剂来曲唑:异位妊娠治疗的新方法
这项非随机前瞻性队列研究在大学医院纳入42例未破裂异位妊娠患者,患者自行选择手术(对照组)、甲氨蝶呤(组1)或来曲唑(组2)治疗。两个药物治疗组各有12/14例(86%)完全缓解;甲氨蝶呤组肝酶显著升高、血小板显著降低,来曲唑组β-hCG下降更快;治疗后3个月甲氨蝶呤组AMH低于来曲唑组和手术组,但β-hCG与AMH下降未达统计学显著。
要点
- 来曲唑组与甲氨蝶呤组完全缓解率相同,均为12/14例(86%)。
- 甲氨蝶呤组肝酶显著升高、血小板计数显著降低。
- 来曲唑组β-hCG下降快于甲氨蝶呤组;3个月时甲氨蝶呤组AMH低于来曲唑组和手术组。
核心结论
- 据作者所知,这是文献中首次报道来曲唑成功用于异位妊娠药物治疗。
- 来曲唑相比化疗药甲氨蝶呤具有令人鼓舞的高缓解率和更好的安全性,应鼓励进一步研究。
研究设计与样本
- 非随机前瞻性队列研究,在大学医院连续纳入42例未破裂异位妊娠患者。
- 患者在接受治疗选择咨询后自行选择手术(对照组)、甲氨蝶呤(组1)或来曲唑(组2)治疗,每组14例。
主要发现
- 两个药物治疗组完全缓解率相同,均为12/14例(86%)。
- 甲氨蝶呤组肝酶显著升高、血小板计数显著降低。
- 来曲唑组β-hCG下降快于甲氨蝶呤组。
- 治疗后3个月,甲氨蝶呤组AMH低于来曲唑组和手术组。
- β-hCG与AMH的下降未达统计学显著。
关键数值与推荐
- 主要结局为血清β-hCG低于实验室免疫检测下限,判定异位妊娠完全缓解。
- 次要结局为卵巢储备生化指标AMH变化及两种药物治疗相比手术治疗的血液学变化。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the use of the aromatase inhibitor letrozole for treatment of ectopic pregnancy compared with methotrexate. DESIGN: Nonrandomized prospective cohort study. SETTING: University hospital. PATIENT(S): A series of 42 consecutive patients with undisturbed ectopic pregnancy. INTERVENTION(S): Counseling on treatment options, including surgical treatment (control group) versus medical treatment with methotrexate (group 1) or letrozole (group 2). MAIN OUTCOME MEASURE(S): Primary outcome: complete resolution of ectopic pregnancy determined by serum human chorionic gonadotropin (β-hCG) levels below laboratory immunoassay detection. SECONDARY OUTCOMES: changes in the biochemical parameter of ovarian reserve, antimüllerian hormone (AMH), and hematologic changes associated with the two medical treatments compared with surgical treatment. RESULT(S): Each treatment group included 14 patients, and each patient made her own treatment choice. Complete resolution of ectopic pregnancy occurred in an equal number of patients: 12 out of 14 (86%) in each of the two medical treatment groups. Methotrexate treatment was associated with statistically significantly higher liver enzymes and lower blood platelets count. The decline in β-hCG levels was faster in the letrozole group when compared with the methotrexate group. Three months after treatment, AMH levels were lower in the methotrexate group when compared with the letrozole and the surgery groups. However, the decline in β-hCG and AMH levels was not statistically significant. CONCLUSION(S): To our knowledge, this is the first report in the literature on the success of letrozole for the medical treatment of ectopic pregnancy. The promisingly high resolution rate and better safety profile that letrozole has compared with a chemotherapeutic agent such as methotrexate should encourage further studies.
引用
- Mitwally MF, Hozayen WG, Hassanin KMA, et al. Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy. Fertil Steril. 2020. PMID: 32622660. doi:10.1016/j.fertnstert.2020.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。